Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Escobar

Showing results (31-40 of 368) with videos related to

Pageof 37
Sort By:
Expert Review of Cardiovascular Therapy|November 11, 2009
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORAVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|December 5, 2018
Cost-effectiveness of EvolocumabCarlos Escobar, Vivencio Barrios
Journal of Atrial Fibrillation|May 13, 2017
Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive DrugsVivencio Barrios, Carlos Escobar
European Heart Journal|October 3, 2008
High resting heart rate: a cardiovascular risk factor or a marker of risk?Carlos Escobar, Vivencio Barrios
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
The heart of Revista Clínica Española, 2012Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy|September 28, 2013
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?Vivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|October 29, 2015
Antihypertensive Medication: On the Right Path?Carlos Escobar, Vivencio Barrios
European Heart Journal|November 9, 2020
Atrial fibrillation, an equivalent of cardiovascular disease riskVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|September 11, 2012
Ischemic heart disease and women: more answers are neededCarlos Escobar, Vivencio Barrios
Future Cardiology|February 4, 2021
Canagliflozin: metabolic, cardiovascular and renal protectionVivencio Barrios, Carlos Escobar
Pageof 37

Showing results (31-40 of 368) with videos related to

Sort By:
Pageof 37
Expert Review of Cardiovascular Therapy|November 11, 2009
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORAVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|December 5, 2018
Cost-effectiveness of EvolocumabCarlos Escobar, Vivencio Barrios
Journal of Atrial Fibrillation|May 13, 2017
Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive DrugsVivencio Barrios, Carlos Escobar
European Heart Journal|October 3, 2008
High resting heart rate: a cardiovascular risk factor or a marker of risk?Carlos Escobar, Vivencio Barrios
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
The heart of Revista Clínica Española, 2012Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy|September 28, 2013
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?Vivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|October 29, 2015
Antihypertensive Medication: On the Right Path?Carlos Escobar, Vivencio Barrios
European Heart Journal|November 9, 2020
Atrial fibrillation, an equivalent of cardiovascular disease riskVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|September 11, 2012
Ischemic heart disease and women: more answers are neededCarlos Escobar, Vivencio Barrios
Future Cardiology|February 4, 2021
Canagliflozin: metabolic, cardiovascular and renal protectionVivencio Barrios, Carlos Escobar
Pageof 37